You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2024

CLINICAL TRIALS PROFILE FOR OLTIPRAZ


✉ Email this page to a colleague

« Back to Dashboard


Clinical Trials for Oltipraz

Trial ID Title Status Sponsor Phase Summary
NCT00006457 ↗ Oltipraz in the Prevention of Lung Cancer in People Who Smoke Completed National Cancer Institute (NCI) Phase 1 RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. PURPOSE: Randomized phase I trial to study the effectiveness of oltipraz in preventing lung cancer in people who smoke.
NCT00006457 ↗ Oltipraz in the Prevention of Lung Cancer in People Who Smoke Completed Northwestern University Phase 1 RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. PURPOSE: Randomized phase I trial to study the effectiveness of oltipraz in preventing lung cancer in people who smoke.
NCT00956098 ↗ Efficacy and Safety of Oltipraz in the Patients With Liver Fibrosis and Cirrhosis Completed CJ HealthCare Corporation Phase 2 This study investigated the effectiveness and safety of oltipraz therapy in treating patients with cirrhosis induced by chronic hepatitis type B or C.
NCT00956098 ↗ Efficacy and Safety of Oltipraz in the Patients With Liver Fibrosis and Cirrhosis Completed HK inno.N Corporation Phase 2 This study investigated the effectiveness and safety of oltipraz therapy in treating patients with cirrhosis induced by chronic hepatitis type B or C.
NCT01373554 ↗ Efficacy and Safety of Oltipraz in the Patients With Non-alcoholic Fatty Liver Disease Completed PharmaKing Phase 2 Dithiolethiones, a novel class of adenosine monophosphate-activated protein kinase (AMPK) activators, prevent insulin resistance through AMPK-dependent p70 ribosomal S6 kinase-1 (S6K1) inhibition. And it is well known that the modulation of S6K1 by oltipraz inhibited the development of insulin resistance and hyperglycemia through the AMPK-S6K1 pathway.Also some research reported that LXRg (a member of the nuclear hormone receptor)-mediated increases in SREBP-1c (the sterol regulatory element-binding protein-1c gene) promote the expression of lipogenic genes and enhance fatty acid synthesis and oltipraz inhibits LXRg and SREBP-c. Therefore, Oltipraz inhibits fatty acid synthesis through AMPK-S6K1 pathway and LXRg-SREBP-1c pathway in liver.
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for Oltipraz

Condition Name

Condition Name
Intervention Trials
Non-Alcoholic Fatty Liver Disease 2
Liver Cirrhosis 1
Liver Fibrosis 1
Lung Cancer 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH
Intervention Trials
Non-alcoholic Fatty Liver Disease 3
Liver Diseases 3
Fatty Liver 3
Liver Cirrhosis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Oltipraz

Trials by Country

Trials by Country
Location Trials
Korea, Republic of 11
United States 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State
Location Trials
North Carolina 1
Illinois 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Oltipraz

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase Trials
Phase 3 2
Phase 2 2
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase Trials
Completed 4
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Oltipraz

Sponsor Name

Sponsor Name
Sponsor Trials
PharmaKing 3
National Cancer Institute (NCI) 1
Northwestern University 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type
Sponsor Trials
Industry 5
NIH 1
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.